PTCT Q4 2018 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$5B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$86M+10.6% YoY

Gross Profit

$83M95.6% margin

Operating Income

-$45M-52.3% margin

Net Income

-$48M-56.0% margin

EPS (Diluted)

$-0.96

QoQ Revenue Growth

+61.1%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$24M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$768M

Stockholders' Equity

$351M

Cash & Equivalents

$228M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86M	$78M	+10.6%
Gross Profit	$83M	$76M	+9.2%
Operating Income	-$45M	$5M	-927.9%
Net Income	-$48M	$1M	-3905.5%

Revenue Segments

Licensing And Collaboration Agreement

$88M100%